A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Sacituzumab Govitecan
Trop-2
antibody–drug conjugate
breast cancer
lay summary
plain language summary
triple-negative breast cancer
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
pubmed:
2
9
2021
medline:
21
10
2021
entrez:
1
9
2021
Statut:
ppublish
Résumé
Sacituzumab Govitecan (also known by the brand name TRODELVY
Identifiants
pubmed: 34467774
doi: 10.2217/fon-2021-0868
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunoconjugates
0
sacituzumab govitecan
M9BYU8XDQ6
Camptothecin
XT3Z54Z28A
Banques de données
ClinicalTrials.gov
['NCT02574455']
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
3911-3924Commentaires et corrections
Type : CommentOn